Skip to main content
. 2021 Nov 22;2021(11):CD004407. doi: 10.1002/14651858.CD004407.pub5

cb‐Swartz 1974.

Study characteristics
Methods Prospective cohort
Participants 59 children aged 1 to 6 years (mean about 2 years)
Interventions MMR vaccine (Merck Institute for Therapeutic Research)
versus
Mumps ‐ rubella vaccine (Merck Institute for Therapeutic Research)
versus
Rubella vaccine (Merck ‐ Meruvax HPV 77‐DE5)
No information about doses and schedule
Outcomes Temperature (37.2 to 38.2 °C; 38.3 to 39.3 °C; over 39.4 °C), lymphadenopathy, enanthema, conjunctivitis, rash, complaints ‐ any (up to 60 days). Follow‐up 7 to 15 days
Funding Source Mixed (government and pharmaceutical industry)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
PCS/RCS ‐ exposed cohort selection High risk There was insufficient information.
PCS/RCS ‐ non‐exposed cohort selection High risk There was insufficient information.
PCS/RCS ‐ comparability High risk No adjustment for confounding
PCS/RCS ‐ assessment of outcome High risk There was insufficient information.
Summary Risk of Bias assessment High risk We had concerns regarding multiple domains such that our confidence in the result is substantially lowered.